Search Results
Results found for "OMass Therapeutics"
- 📰 GPCR Weekly News, January 23 to 29, 2023
Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics GPCR Jobs Scientist/Senior Scientist (Research Software Engineer) Senior Scientist – Native Mass Spectrometry Speculative Applications (Protein Biochemistry) Speculative Applications (Mass Spectrometry) Speculative
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
The Future of GPCR Therapeutics in Metabolic Disease Even with GLP-1 and GIP agonists reshaping diabetes Why it matters: Muscle mass shapes longevity, resilience, and overall metabolic health.
- Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor
- GPCR Happy Hour – Boston, Sept 2025
delivers cutting-edge imaging and analysis that accelerates the discovery of new and life-changing therapeutics comprehensive approach enables Axxam to support clients worldwide in identifying and optimizing new therapeutic
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
Receptor Bryan Roth and Brian Krumm for their excellent study on Molecular glues as potential GPCR therapeutics November 7th : Drug Disposition in Physiological Tissues as a Therapeutic Variable. December 5th : Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit. modulation of the prostaglandin EP4 receptor GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics
- 📰 GPCR Weekly News, July 1 to 7, 2024
September 5th to 26th, 2024 Overview: GPCRs have been and arguably still are the most prolific and fertile therapeutic trade-offs in whitefly G protein-coupled receptor kinases in hypertension: physiology, pathogenesis, and therapeutic proteins block the internalization of cognate GPCRs and disrupt downstream intracellular signaling Therapeutic acute and chronic relaxin-3 receptor (RXFP3) activation in the rat retrosplenial cortex Unveiling the therapeutic
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Industry News MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3 Certa Therapeutics proteins for biology and health research Innovate UK announced the winners of its Transforming Cancer Therapeutics
- 📰 GPCR Weekly News, October 2 to 8, 2023
This week's highlight: Congrats to our partner GPCR Therapeutics, on their expansion into fibrosis with selectivity Industry News Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets GPCR Therapeutics
- What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024
Arm's Race' Developments Five protein-design questions that still challenge AI Prix Galien USA: Domain Therapeutics Nominated for the Prestigious Best Startup Award Tectonic Therapeutic Announces Positive Phase 1a Results 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic
- 📰 GPCR Weekly News, August 14 to 20, 2023
Congrats to the GPCR Therapeutics team for their recent paper in the American College of Clinical Pharmacology GPCR Symposium on 'GPCRs as Therapeutic Modalities'. and oligomerization Molecular Insights into GPCR Mechanisms for Drugs of Abuse Industry News 'GPCR Therapeutics Nordisk to Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic
- 📰 GPCR Weekly News, February 13 to 19, 2023
GPCR Binders, Drugs, and more Novel targets for potential therapeutic use in Diabetes mellitus. and Pharmacology Scientist/Senior Scientist (Research Software Engineer) Senior Scientist – Native Mass Spectrometry Speculative Applications (Protein Biochemistry) Speculative Applications (Mass Spectrometry
- 📰 GPCR Weekly News, September 11 to 17, 2023
Kevin Wright on his new position as Director of Targeted and Immuno-oncology at GPCR Therapeutics, our GPCR Symposium on 'GPCRs as Therapeutic Modalities' with Richa Tyagi, Dr. Terry Kenakin, Dr. Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting
- 📰 GPCR Weekly News, May 1 to 7, 2023
Industry News Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023 Neurocrine Biosciences Reports First Quarter 2023 Financial Results Find Therapeutics welcomes critical, we cannot think about one size fits all” Dr Pina Cardarelli, Chief Scientific Officer, GPCR Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics
- 📰 GPCR Weekly News, June 3 to June 9, 2024
Adhesion GPCRs A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets Services and Cube Biotech Collaborate to Enhance Cryo-EM Enabled Gene to Structure Workflow Domain Therapeutics ACTH-Dependent Cushing’s Syndrome (ADCS) Septerna Presents Preclinical Data at ENDO 2024 Highlighting Therapeutic
- 📰 GPCR Weekly News, August 28 to September 3, 2023
GPCR Symposium on 'GPCRs as Therapeutic Modalities' Showcase your project with a 1-minute abstract video Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies Confo Therapeutics 21st Annual Global Healthcare Conference CEO Raymond Stevens to Speak at STAT Future Summit on Obesity Therapeutics Function and Biased Signaling" at the DOT NEW October 3, 2023 | FREE Seminar: Changing paradigm on Therapeutics
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
Modeling tools to understand how restricted diffusion in tissues like tumors slows offset and improves therapeutic drug hiding in fat tissue may stay in the body for days, but if it never reaches the target site, the therapeutic
- How Fast Does a Drug Work?
essential for pipeline efficiency: How fast a ligand binds (k₁) and how long it stays bound (k₂) can alter therapeutic When does onset rate dictate therapeutic onset, and when does offset rate predict duration?
- 📰 GPCR Weekly News, October 23 to 29, 2023
This week's highlight: Congratulations to the GPCR Therapeutics team for their publication on improving Orion's COO, Shared Innovative Insights at LSBC Central European Life Science Investment Conference GPCR Therapeutics Late-Stage Development Progress Parker Moss to Join Exscientia as EVP, Corporate Development Confo Therapeutics
- 📰 GPCR Weekly News, August 7 to 13, 2023
GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? npr-38 regulates avoidance and stress-induced sleep in Caenorhabditis elegans Towards the convergent therapeutic Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program Structure Therapeutics
- 📰 GPCR Weekly News, June 24 to 30, 2024
Bryan Roth and Brian Krumm for their study on Molecular glues as potential GPCR therapeutics Drs. breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects GPR56: A potential therapeutic via site-selective activation of mTOR GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics
- Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!
appreciate the incredible versatility of GPCRs and how small molecules can affect their behavior for therapeutic Learn how to therapeutically exploit GPCRs (Physiology’s ‘Swiss Army Knife’) vast repertoire of ways Adjust ligand kinetics and tissue disposition for optimal therapeutic activity.
- GPR108 is required for gambogic acid inhibiting NF-κB signaling in cancer
Herein, we identified GPR108, a GPCR protein described in innate immune system, is a potential therapeutic Overall, our findings supported GPR108 as a promising therapeutic target of cancer, and provided a small
- 📰 GPCR Weekly News, January 29 to February 4, 2024
Xavier Leroy for his new role as CEO of GIO Therapeutics Dr. Molecular mechanism of GPCR spatial organization at the plasma membrane Industry News Launch of GIO Therapeutics , founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation AVROBIO and Tectonic Therapeutic Announce Merger Trevena Inc Elevates Barry
- Allosteric modulation of GPCRs: From structural insights to in silico drug discovery
orthosteric site), allosteric modulators offer new avenues for the regulation of GPCR function with potential therapeutic today, will facilitate structure-based discovery and development of allosteric modulators as novel therapeutic
- 📰 GPCR Weekly News, April 10 to 16, 2023
Allosteric GPCR Drug Discovery from the 2nd Annual GPCRs-Targeted Drug Discovery Summit, Boston MA Pathios Therapeutics Michel Bouvier received the title of Doctor Honoris Causa from the Université de Montpellier Domain Therapeutics presented 3 posters at AACR 2023 Exscientia presented a poster at AACR 2023 Pathios Therapeutics presented Swiss Biotech Day (April 24 - 25, 2023) ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics
- 📰 GPCR Weekly News, March 25 to March 31, 2024
cAMP-PKA-CREB signaling pathway based on network pharmacology and bioinformatics analysis Unveiling the therapeutic News Monash University pharmaceutical scientists honoured in NHMRC Research Excellence Awards Domain Therapeutics Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Confo Therapeutics Development In Endocrine And Metabolic Diseases How biotech companies are using AI to design drugs GPCR Therapeutics
- Inverse Agonists, Lymphatic Fixes & β-arrestin Tricks
Collaboration is the catalyst—let’s redefine what’s possible in GPCR-driven therapeutics.
- RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany...
So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic
- Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System
tools used to manipulate GPCR activity in an orthosteric site-independent manner to compounds with therapeutic development for each receptor, as well as the structural, signaling, pathophysiologic consequences, and therapeutic
- Nanobodies: New Dimensions in GPCR Signaling Research
the development of more selective drugs capable of modulating specific signaling pathways, improving therapeutic This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending its conformation, protects the Schiff base, and prevents protein degradation, potentially offering therapeutic Nanobodies: A Review of Generation, Diagnostics and Therapeutics.











